Biosafety features of lentiviral vectors

Human Gene Therapy

Volumn 24, Issue 2, 2013, Pages 132-142

  Schambach, Axel ^a   Zychlinski, Daniela ^a   Ehrnstroem, Birgitta ^a   Baum, Christopher ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; INTEGRASE; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; POL PROTEIN; REV PROTEIN; SELF INACTIVATING VECTOR; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VPR PROTEIN; ZIDOVUDINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; BIOSAFETY; CELL IMMORTALIZATION; CHRONIC GRANULOMATOUS DISEASE; DNA MODIFICATION; DNA RESPONSIVE ELEMENT; DRUG DESIGN; ENHANCER REGION; GENE CASSETTE; GENE DELETION; GENE INTERACTION; GENETIC RISK; GENOTOXICITY; GERM LINE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INSERTIONAL MUTAGENESIS; INTRON; LENTIVIRINAE; LONG TERMINAL REPEAT; MALIGNANT TRANSFORMATION; MURINE LEUKEMIA VIRUS; MUTAGENESIS; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; POLYADENYLATION; POSTTRANSCRIPTIONAL GENE SILENCING; PROMOTER REGION; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; RNA DEGRADATION; RNA PROCESSING; SEVERE COMBINED IMMUNODEFICIENCY; THALASSEMIA; TRANSCRIPTION TERMINATION; VIRUS CARCINOGENESIS; VIRUS DNA CELL DNA INTERACTION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS REPLICATION; VIRUS SHEDDING; WISKOTT ALDRICH SYNDROME; WOODCHUCK HEPATITIS VIRUS;

ENHANCER ELEMENTS, GENETIC; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; LENTIVIRUS; LENTIVIRUS INFECTIONS; MUTAGENESIS, INSERTIONAL; PROMOTER REGIONS, GENETIC; RNA PROCESSING, POST-TRANSCRIPTIONAL; VIRUS ACTIVATION; VIRUS INTEGRATION; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84874289993     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.229     Document Type: Review

References (114)

1. Agudo, J., Ruzo, A., Kitur, K., et al. (2012). A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade. Mol. Ther. 20, 2257-2267.
2. Almarza, D., Bussadori, G., Navarro, M., et al. (2011). Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Ther. 18, 674-681.
3. Arumugam, P.I., Higashimoto, T., Urbinati, F., et al. (2009a). Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region. Mol. Ther. 17, 1929-1937.
4. Arumugam, P.I., Urbinati, F., Velu, C.S., et al. (2009b). The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PloS one. 4, e6995.
5. Berkowitz, R.D., Hammarskjold, M.L., Helga-Maria, C., et al. (1995). 5' regions of HIV-1 RNAs are not sufficient for encapsidation: implications for the HIV-1 packaging signal. Virology. 212, 718-723.
6. Biffi, A., Bartolomae, C.C., Cesana, D., et al. (2011). Lentiviralvector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood. 117, 5332-5339.
7. Billings, P.R., Hubbard, R., and Newman, S.A. (1999). Human germline gene modification: a dissent. Lancet. 353, 1873-1875.
8. Blissenbach, M., Grewe, B., Hoffmann, B., et al. (2010). Nuclear RNA export and packaging functions of HIV-1 Rev revisited. J. Virol. 84, 6598-6604.
9. Blomer, U., Gruh, I., Witschel, H., et al. (2005). Shuttle of lentiviral vectors via transplanted cells in vivo. Gene Ther. 12, 67-74.
10. Bokhoven, M., Stephen, S.L., Knight, S., et al. (2009). Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83, 283-294.
11. Bouchard, M.J., and Schneider, R.J. (2004). The enigmatic X gene of hepatitis B virus. J. Virol. 78, 12725-12734.
12. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
13. Brandt, S., Blissenbach, M., Grewe, B., et al. (2007). Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation. PLoS pathogens. 3, e54.
14. Brenner, M.K., and Heslop, H.E. (2003). Is retroviral gene marking too dangerous to use? Cytotherapy. 5, 190-193.
15. Brown, B.D., and Naldini, L. (2009). Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10, 578-585.
16. Brown, B.D., Venneri, M.A., Zingale, A., et al. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585-591.
17. Brown, B.D., Cantore, A., Annoni, A., et al. (2007a). A micro-RNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood. 110, 4144-4152.
18. Brown, B.D., Gentner, B., Cantore, A., et al. (2007b). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457-1467.
19. Buchholz, C.J., Muhlebach, M.D., and Cichutek, K. (2009). Lentiviral vectors with measles virus glycoproteins-dream team for gene transfer? Trends Biotechnol. 27, 259-265.
20. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 326, 818-823.
21. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 467, 318-322.
22. Cesana, D., Sgualdino, J., Rudilosso, L., et al. (2012). Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J. Clin. Invest. 122, 1667-1676.
23. Chong, H., and Vile, R.G. (1996). Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Ther. 3, 624-629.
24. Cornils, K., Lange, C., Schambach, A., et al. (2009). Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol. Ther. 17, 131-143.
25. Cui, Y., Iwakuma, T., and Chang, L.J. (1999). Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol. 73, 6171-6176.
26. Demaison, C., Parsley, K., Brouns, G., et al. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13, 803-813.
27. Donahue, R.E., Kessler, S.W., Bodine, D., et al. (1992). Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125-1135.
28. D'Souza, V., and Summers, M.F. (2005). How retroviruses select their genomes. Nat. Rev. Microbiol. 3, 643-655.
29. Dull, T., Zufferey, R., Kelly, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol. 72, 8463-8471.
30. Emi, N., Friedmann, T., and Yee, J.K. (1991). Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol. 65, 1202-1207.
31. Enkirch, T., Kneissl, S., Hoyler, B., et al. (2012). Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins. Gene Ther. 20, 16-23.
32. Evans-Galea, M.V., Wielgosz, M.M., Hanawa, H., et al. (2007). Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol. Ther. 15, 801-809.
33. Fassati, A. (2006). HIV infection of non-dividing cells: a divisive problem. Retrovirology. 3, 74.
34. Fassati, A. (2012). Multiple roles of the capsid protein in the early steps of HIV-1 infection. Virus research. 170, 15-24.
35. Frecha, C., Szecsi, J., Cosset, F.L., et al. (2008). Strategies for targeting lentiviral vectors. Curr Gene Ther. 8, 449-460.
36. Frecha, C., Costa, C., Negre, D., et al. (2012). A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood. 119, 1139-1150.
37. Gaszner, M., and Felsenfeld, G. (2006). Insulators: exploiting transcriptional and epigenetic mechanisms. Nature reviews. Genetics. 7, 703-713.
38. Gentner, B., Schira, G., Giustacchini, A., et al. (2009). Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods. 6, 63-66.
39. Gentner, B., Visigalli, I., Hiramatsu, H., et al. (2010). Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci Transl Med. 2, 58ra84.
40. Gijsbers, R., Ronen, K., Vets, S., et al. (2010). LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther. 18, 552-560.
41. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302, 415-419.
42. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
43. Hammond, S.M., and Sharpless, N.E. (2008). HMGA2, micro-RNAs, and stem cell aging. Cell. 135, 1013-1016.
44. Hanawa, H., Yamamoto, M., Zhao, H., et al. (2009). Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol. Ther. 17, 667-674.
45. Harrison, G.P., Miele, G., Hunter, E., et al. (1998). Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J. Virol. 72, 5886-5896.
46. Heckl, D., Schwarzer, A., Haemmerle, R., et al. (2012). Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol. Ther. 20, 1187-1195.
47. Hibbert, C.S., Mirro, J., and Rein, A. (2004). mRNA molecules containing murine leukemia virus packaging signals are encapsidated as dimers. J. Virol. 78, 10927-10938.
48. Higashimoto, T., Urbinati, F., Perumbeti, A., et al. (2007). The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther. 14, 1298-1304.
49. Hope, T. (2002). Improving the post-transcriptional aspects of lentiviral vectors. Curr Top Microbiol Immunol. 261, 179-189.
50. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 118, 3143-3150.
51. Hu, J., Renaud, G., Gomes, T.J., et al. (2008). Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol. Ther. 16, 1617-1623.
52. Imahashi, M., Nakashima, M., and Iwatani, Y. (2012). Antiviral mechanism and biochemical basis of the human APOBEC3 family. Front. Microbiol. 3, 250.
53. Kaye, J.F., and Lever, A.M. (1998). Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation. J. Virol. 72, 5877-5885.
54. Kneissl, S., Abel, T., Rasbach, A., et al. (2012). Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PloS one. 7, e46667.
55. Knight, S., Bokhoven, M., Collins, M., et al. (2010). Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat. J. Virol. 84, 4856-4859.
56. Knight, S., Zhang, F., Mueller-Kuller, U., et al. (2012). Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J. Virol. 86, 9088-9095.
57. Kustikova, O., Fehse, B., Modlich, U., et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 308, 1171-1174.
58. Leath, A., and Cornetta, K. (2012). Developing novel lentiviral vectors into clinical products. Methods Enzymol. 507, 89-108.
59. Levy, C., Amirache, F., Costa, C., et al. (2012). Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in In Vivo-like transduction of human T and B cells. Mol. Ther. 20, 1699-1712.
60. Lewinski, M.K., and Bushman, F.D. (2005). Retroviral DNA integration-mechanism and consequences. Adv. Genetics. 55, 147-181.
61. Lewinski, M.K., Yamashita, M., Emerman, M., et al. (2006). Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS pathogens. 2, e60.
62. Li, Z., Dullmann, J., Schiedlmeier, B., et al. (2002). Murine leukemia induced by retroviral gene marking. Science. 296, 497.
63. Li, C.L., Xiong, D., Stamatoyannopoulos, G., et al. (2009). Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol. Ther. 17, 716-724.
64. Maetzig, T., Brugman, M.H., Bartels, S., et al. (2011). Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood. 117, 3053-3064.
65. May, C., Rivella, S., Callegari, J., et al. (2000). Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 406, 82-86.
66. Miller, A.D. (1990). Retrovirus packaging cells. Hum. Gene Ther. 1, 5-14.
67. Mitchell, R.S., Beitzel, B.F., Schroder, A.R., et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234.
68. Modlich,U., Navarro, S., Zychlinski, D., et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 17, 1919-1928.
69. Moiani, A., Paleari, Y., Sartori, D., et al. (2012). Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J. Clin. Invest. 122, 1653-1666.
70. Montini, E., Cesana, D., Schmidt, M., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-96.
71. Montini, E., Cesana, D., Schmidt, M., et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC Gene Ther. J. Clin. Invest. 119, 964-975.
72. Moreno-Carranza, B., Gentsch, M., Stein, S., et al. (2009). Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther. 16, 111-118.
73. Mulligan, R.C. (1993). The basic science of gene therapy. Science. 260, 926-932.
74. Muriaux, D., and Darlix, J.L. (2010). Properties and functions of the nucleocapsid protein in virus assembly. RNA biology. 7, 744-753.
75. Naldini, L. (2011). Ex vivo gene transfer and correction for cellbased therapies. Nat. Rev. Genet. 12, 301-315.
76. Naldini, L., Blomer, U., Gallay, P., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272, 263-267.
77. Ng, Y.Y., Baert, M.R., Pike-Overzet, K., et al. (2010). Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia. 24, 1617-1630.
78. Ocwieja, K.E., Brady, T.L., Ronen, K., et al. (2011). HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS pathogens. 7, e1001313.
79. O'Neill, L.S., Skinner, A.M., Woodward, J.A., et al. (2010). Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles. J Gene Med. 12, 463-476.
80. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 12, 401-409.
81. Paillart, J.C., Dettenhofer, M., Yu, X.F., et al. (2004). First snapshots of the HIV-1 RNA structure in infected cells and in virions. The Journal of biological chemistry. 279, 48397-48403.
82. Pan, Y.W., Scarlett, J.M., Luoh, T.T., et al. (2007). Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo. J Virol. 81, 639-649.
83. Pawliuk, R., Westerman, K.A., Fabry, M.E., et al. (2001). Correction of sickle cell disease in transgenic mouse models by Gene Ther. Science. 294, 2368-2371.
84. Persons, D.A., and Baum, C. (2011). Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol. Ther. 19, 229-231.
85. Pike-Overzet, K., Rodijk, M., Ng, Y.Y., et al. (2011). Correction of murine Rag1 deficiency by self-inactivating lentiviral vectormediated gene transfer. Leukemia. 25, 1471-1483.
86. Ramezani, A., Hawley, T.S., and Hawley, R.G. (2008). Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells. 26, 3257-3266.
87. Roselli, E.A., Mezzadra, R., Frittoli, M.C., et al. (2010). Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med. 2, 315-328.
88. Ryu, B.Y., Evans-Galea, M.V., Gray, J.T., et al. (2008). An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood. 111, 1866-1875.
89. Scaramuzza, S., Biasco, L., Ripamonti, A., et al. (2012). Preclinical safety and efficacy of human CD34( + ) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther. 21, 175-184.
90. Schaller, T., Ocwieja, K.E., Rasaiyaah, J., et al. (2011). HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS pathogens. 7, e1002439.
91. Schambach, A., Wodrich, H., Hildinger, M., et al. (2000). Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. 2, 435-445.
92. Schambach, A., Bohne, J., Baum, C., et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13, 641-645.
93. Schambach, A., Galla, M., Maetzig, T., et al. (2007). Improving transcriptional termination of self-inactivating gammaretroviral and lentiviral vectors. Mol Ther. 15, 1167-1173.
94. Schmidt, M., Carbonaro, D.A., Speckmann, C., et al. (2003). Clonality analysis after retroviral-mediated gene transfer to CD34 + cells from the cord blood of ADA-deficient SCID neonates. Nat. Med. 9, 463-8.
95. Schroder, A.R., Shinn, P., Chen, H., et al. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 110, 521-529.
96. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204.
97. Stoltzfus, C.M., and Madsen, J.M. (2006). Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr. HIV Res. 4, 43-55.
98. Suerth, J.D., Maetzig, T., Brugman, M.H., et al. (2012). Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol. Ther. 20, 1022-1032.
99. Tai, C.K., and Kasahara, N. (2008). Replication-competent retrovirus vectors for cancer Gene Ther. Front. Biosci. 13, 3083-3095.
100. Themis, M., Waddington, S.N., Schmidt, M., et al. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 12, 763-771.
101. Thomas, C.E., Ehrhardt, A., and Kay, M.A. (2003). Progress and problems with the use of viral vectors for Gene Ther. Nat. Rev. Genet. 4, 346-358.
102. Uren, A.G., Kool, J., Berns, A., et al. (2005). Retroviral insertional mutagenesis: past, present and future. Oncogene. 24, 7656-7672.
103. Voelkel, C., Galla,M., Dannhauser, P.N., et al. (2012). Pseudotypeindependent nonspecific uptake of gammaretroviral and lentiviral particles in human cells. Hum Gene Ther. 23, 274-286.
104. Warlich, E., Kuehle, J., Cantz, T., et al. (2011). Lentiviral Vector Design and Imaging Approaches to Visualize the Early Stages of Cellular Reprogramming. Mol. Ther. 19, 782-789.
105. Williams, D.A., Lemischka, I.R., Nathan, D.G., et al. (1984). Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature. 310, 476-480.
106. Xu, K., Ma, H., McCown, T.J., et al. (2001). Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3, 97-104.
107. Yamagata, Y., Parietti, V., Stockholm, D., et al. (2012). Lentiviral transduction of CD34( + ) cells induces genome-wide epigenetic modifications. PloS one. 7, e48943.
108. Yu, S.F., von Ruden, T., Kantoff, P.W., et al. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 83, 3194-3198.
109. Zaiss, A.K., Son, S., and Chang, L.J. (2002). RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J. Virol. 76, 7209-7219.
110. Zanta-Boussif, M.A., Charrier, S., Brice-Ouzet, A., et al. (2009). Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther. 16, 605-619.
111. Zennou, V., Petit, C., Guetard, D., et al. (2000). HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 101, 173-85.
112. Zhou, S., Mody, D., DeRavin, S.S., et al. (2010). A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood. 116, 900-8.
113. Zufferey, R., Donello, J.E., Trono, D., et al. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886-2892.
114. Zychlinski, D., Schambach, A., Modlich, U., et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718-25.